Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?
Identifieur interne : 000847 ( Main/Exploration ); précédent : 000846; suivant : 000848Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?
Auteurs : Bruno Charpiat [France] ; Nathalie Bleyzac [France] ; Michel Tod [France]Source :
- Clinical drug investigation [ 1179-1918 ] ; 2020.
Abstract
During the ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more attention should be paid to the balance of risks and benefits associated with proton pump inhibitors for the following reasons. One of the main functions of gastric juice is to inactivate swallowed microorganisms, thereby inhibiting infectious agents from reaching the intestine. Studies have documented that proton pump inhibitors are a risk factor for rotavirus, influenza virus, norovirus, and Middle East respiratory syndrome coronavirus infections, and are associated with an increased risk of acute gastroenteritis during periods of highest circulation of enteric viruses. In light of the evidence for gastrointestinal infection implying a fecal-oral transmission of SARS-CoV-2 and given the magnitude of the SARS-CoV-2/coronavirus disease 2019 pandemic, associated with the widespread misuse of proton pump inhibitors, this suggests that we should not rule out the hypothesis that patients treated with proton pump inhibitors may be more at risk of being infected by SARS-CoV-2.
DOI: 10.1007/s40261-020-00963-x
PubMed: 32779119
PubMed Central: PMC7417108
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?</title><author><name sortKey="Charpiat, Bruno" sort="Charpiat, Bruno" uniqKey="Charpiat B" first="Bruno" last="Charpiat">Bruno Charpiat</name><affiliation wicri:level="3"><nlm:affiliation>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France. bruno.charpiat@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bleyzac, Nathalie" sort="Bleyzac, Nathalie" uniqKey="Bleyzac N" first="Nathalie" last="Bleyzac">Nathalie Bleyzac</name><affiliation wicri:level="3"><nlm:affiliation>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins Cedex</wicri:regionArea><wicri:noRegion>Oullins Cedex</wicri:noRegion><orgName type="university">Université Claude Bernard Lyon 1</orgName><placeName><settlement type="city">Lyon</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation></author><author><name sortKey="Tod, Michel" sort="Tod, Michel" uniqKey="Tod M" first="Michel" last="Tod">Michel Tod</name><affiliation wicri:level="3"><nlm:affiliation>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins Cedex</wicri:regionArea><wicri:noRegion>Oullins Cedex</wicri:noRegion><orgName type="university">Université Claude Bernard Lyon 1</orgName><placeName><settlement type="city">Lyon</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32779119</idno><idno type="pmid">32779119</idno><idno type="doi">10.1007/s40261-020-00963-x</idno><idno type="pmc">PMC7417108</idno><idno type="wicri:Area/Main/Corpus">000648</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000648</idno><idno type="wicri:Area/Main/Curation">000648</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000648</idno><idno type="wicri:Area/Main/Exploration">000648</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?</title><author><name sortKey="Charpiat, Bruno" sort="Charpiat, Bruno" uniqKey="Charpiat B" first="Bruno" last="Charpiat">Bruno Charpiat</name><affiliation wicri:level="3"><nlm:affiliation>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France. bruno.charpiat@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bleyzac, Nathalie" sort="Bleyzac, Nathalie" uniqKey="Bleyzac N" first="Nathalie" last="Bleyzac">Nathalie Bleyzac</name><affiliation wicri:level="3"><nlm:affiliation>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins Cedex</wicri:regionArea><wicri:noRegion>Oullins Cedex</wicri:noRegion><orgName type="university">Université Claude Bernard Lyon 1</orgName><placeName><settlement type="city">Lyon</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation></author><author><name sortKey="Tod, Michel" sort="Tod, Michel" uniqKey="Tod M" first="Michel" last="Tod">Michel Tod</name><affiliation wicri:level="3"><nlm:affiliation>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins Cedex</wicri:regionArea><wicri:noRegion>Oullins Cedex</wicri:noRegion><orgName type="university">Université Claude Bernard Lyon 1</orgName><placeName><settlement type="city">Lyon</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation></author></analytic><series><title level="j">Clinical drug investigation</title><idno type="eISSN">1179-1918</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">During the ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more attention should be paid to the balance of risks and benefits associated with proton pump inhibitors for the following reasons. One of the main functions of gastric juice is to inactivate swallowed microorganisms, thereby inhibiting infectious agents from reaching the intestine. Studies have documented that proton pump inhibitors are a risk factor for rotavirus, influenza virus, norovirus, and Middle East respiratory syndrome coronavirus infections, and are associated with an increased risk of acute gastroenteritis during periods of highest circulation of enteric viruses. In light of the evidence for gastrointestinal infection implying a fecal-oral transmission of SARS-CoV-2 and given the magnitude of the SARS-CoV-2/coronavirus disease 2019 pandemic, associated with the widespread misuse of proton pump inhibitors, this suggests that we should not rule out the hypothesis that patients treated with proton pump inhibitors may be more at risk of being infected by SARS-CoV-2.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">32779119</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1918</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Clinical drug investigation</Title><ISOAbbreviation>Clin Drug Investig</ISOAbbreviation></Journal><ArticleTitle>Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?</ArticleTitle><Pagination><MedlinePgn>897-899</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40261-020-00963-x</ELocationID><Abstract><AbstractText>During the ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more attention should be paid to the balance of risks and benefits associated with proton pump inhibitors for the following reasons. One of the main functions of gastric juice is to inactivate swallowed microorganisms, thereby inhibiting infectious agents from reaching the intestine. Studies have documented that proton pump inhibitors are a risk factor for rotavirus, influenza virus, norovirus, and Middle East respiratory syndrome coronavirus infections, and are associated with an increased risk of acute gastroenteritis during periods of highest circulation of enteric viruses. In light of the evidence for gastrointestinal infection implying a fecal-oral transmission of SARS-CoV-2 and given the magnitude of the SARS-CoV-2/coronavirus disease 2019 pandemic, associated with the widespread misuse of proton pump inhibitors, this suggests that we should not rule out the hypothesis that patients treated with proton pump inhibitors may be more at risk of being infected by SARS-CoV-2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Charpiat</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-7885-1727</Identifier><AffiliationInfo><Affiliation>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France. bruno.charpiat@chu-lyon.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleyzac</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tod</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins Cedex, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Drug Investig</MedlineTA><NlmUniqueID>9504817</NlmUniqueID><ISSNLinking>1173-2563</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32779119</ArticleId><ArticleId IdType="doi">10.1007/s40261-020-00963-x</ArticleId><ArticleId IdType="pii">10.1007/s40261-020-00963-x</ArticleId><ArticleId IdType="pmc">PMC7417108</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li></settlement><orgName><li>Université Claude Bernard Lyon 1</li></orgName></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Charpiat, Bruno" sort="Charpiat, Bruno" uniqKey="Charpiat B" first="Bruno" last="Charpiat">Bruno Charpiat</name></region><name sortKey="Bleyzac, Nathalie" sort="Bleyzac, Nathalie" uniqKey="Bleyzac N" first="Nathalie" last="Bleyzac">Nathalie Bleyzac</name><name sortKey="Bleyzac, Nathalie" sort="Bleyzac, Nathalie" uniqKey="Bleyzac N" first="Nathalie" last="Bleyzac">Nathalie Bleyzac</name><name sortKey="Tod, Michel" sort="Tod, Michel" uniqKey="Tod M" first="Michel" last="Tod">Michel Tod</name><name sortKey="Tod, Michel" sort="Tod, Michel" uniqKey="Tod M" first="Michel" last="Tod">Michel Tod</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000847 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000847 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32779119
|texte= Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32779119" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |